The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs

BET bromodomain inhibitors are very promising novel anticancer agents, however, single therapy does not cause tumor regression in mice, suggesting the need for combination therapy. After screening a library of 2697 small molecule compounds, we found that two classes of compounds, the quinone-contain...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncotarget
Main Authors: Liu, Pei Y., Sokolowski, Nicholas, Guo, Su T., Siddiqi, Faraz, Atmadibrata, Bernard, Telfer, Thomas J., Sun, Yuting, Zhang, Lihong, Yu, Denise, Mccarroll, Joshua, Liu, Bing, Yang, Rui H., Guo, Xiang Y., Tee, Andrew E., Itoh, Ken, Wang, Jenny, Kavallaris, Maria, Haber, Michelle, Norris, Murray D., Cheung, Belamy B., Byrne, Jennifer A., Ziegler, David S., Marshall, Glenn M., Dinger, Marcel E., Codd, Rachel, Zhang, Xu D., Liu, Tao
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2016
主題:
Research Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346709/
https://ncbi.nlm.nih.gov/pubmed/27764794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12640
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍